PMID

Data

Article Title

Organization

Potent, Selective, and Cell Active Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor Developed by Structure-Based Virtual Screening and Hit Optimization.

Shandong University

Discovery of a Dual PRMT5-PRMT7 Inhibitor.

University Of Toronto

Discovery of 2-substituted-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-1,2,3,4-tetrahydroisoquinoline-6-carboxamide as potent and selective protein arginine methyltransferases 5 inhibitors: Design, synthesis and biological evaluation.

Shanghai Institute Of Materia Medica

Nucleoside protein arginine methyltransferase 5 (PRMT5) inhibitors.

Prelude Therapeutics

Discovery of new potent protein arginine methyltransferase 5 (PRMT5) inhibitors by assembly of key pharmacophores from known inhibitors.

University Of Jinan

Discovery of Potent and Selective Covalent Protein Arginine Methyltransferase 5 (PRMT5) Inhibitors.

Prelude Therapeutics

Protein Arginine Methyltransferase 5 (PRMT5) as an Anticancer Target and Its Inhibitor Discovery.

Sun Yat-Sen University

LLY-283, a Potent and Selective Inhibitor of Arginine Methyltransferase 5, PRMT5, with Antitumor Activity.

Lilly Research Laboratories

Identification of a novel selective small-molecule inhibitor of protein arginine methyltransferase 5 (PRMT5) by virtual screening, resynthesis and biological evaluations.

University Of Jinan

An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED.

Novartis Institutes For Biomedical Research